The concurrent rise of undertreated pain and opiate abuse poses a unique challenge to physicians and researchers alike. A focal, noninvasive form of brain stimulation called repetitive transcranial magnetic stimulation (rTMS) has been shown to produce acute and chronic analgesic effects when applied to dorsolateral prefrontal cortex (DLPFC), but the anatomical and pharmacological mechanisms by which prefrontal rTMS induces analgesia remain unclear. Data suggest that DLPFC mediates top-down analgesia via gain modulation of the supraspinal opioidergic circuit. This potential pathway might explain how prefrontal rTMS reduces pain. The purpose of this sham-controlled, double-blind, crossover study was to determine whether left DLPFC rTMS-induced analgesia was sensitive to l-opioid blockade. Twenty-four healthy volunteers were randomized to receive real or sham TMS after either intravenous saline or naloxone pretreatment. Acute hot and cold pain via quantitative sensory testing and hot allodynia via block testing on capsaicin-treated skin were assessed at baseline and at 0, 20, and 40 minutes after TMS treatment. When compared to sham, real rTMS reduced hot pain and hot allodynia. Naloxone pretreatment significantly reduced the analgesic effects of real rTMS. These results demonstrate that left DLPFC rTMS-induced analgesia requires opioid activity and suggest that rTMS drives endogenous opioidergic pain relief in the human brain. Further studies with chronic dosing regimens of drugs that block or augment the actions of opiates are needed to determine whether TMS can augment opiates in chronic or postoperative pain management. Ó
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Introduction
The concurrent rise of opiate abuse and undertreated pain continues to drive interest in noninvasive brain stimulation techniques that may diminish pain [25,51,68]. One brain region that has emerged as a target of such stimulation is the dorsolateral prefrontal cortex (DLFPC). Studies have shown that stimulating DLPFC with transcranial direct current stimulation or repetitive transcranial magnetic stimulation (rTMS) reduces experimentally induced pain [13,54,61] as well as chronic pain [4, 17, 46] . In 2 different postoperative studies, patients who received a single session of left DLPFC rTMS after gastric bypass surgery self-administered 40% less morphine than controls who received sham stimulation [16, 19] . Despite these positive results, there are conflicting reports about the extent to which rTMS produces a clinically relevant pain reduction [55] . An important step toward evaluating DLPFC rTMS as a potential analgesic intervention is to determine the pharmacological mechanisms by which it produces analgesia.
The periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) are critical components of a supraspinal opioidergic circuit (SOC) that modulates pain, the subjective experience frequently linked to nociception [6, 7, 33, 49] . There are several lines of indirect evidence that cingulofrontal regions like DLPFC or anterior cingulate cortex can drive top-down analgesia via gain modulation of the SOC. These include: 1) anatomical connectivity as evidenced by retrograde tracing [3,21] and fos immunoreactivity [48] in laboratory animals and diffusion tensor imaging [37] in humans; 2) physiological connectivity as evidenced by electrical or chemical stimulation in rodents, which alter PAG-RVM physiology and induce analgesia in an intensity-and dose-dependent manner [23, 39] ; 3) pharmacological connectivity as evidenced by the shared capacity for opioid release, opiate binding, and opiate-mediated activation [9,12,60]; and 4) functional connectivity as evidenced by naloxone-reversible blood oxygen level-dependent (BOLD) signal coupling during placebo analgesia [32, 57] .
